Today's Top Story

Hua Phase III diabetes data make good on glucokinase but disappoint investors

Hua’s announcement that glucokinase activator dorzagliatin met its endpoints in a Phase III diabetes study marks a watershed moment for a target whose disease-modifying potential was long stymied by ...

Company News

FDA: Mineral oil unlikely culprit in REDUCE-IT outcome

FDA sliced and diced the CVOT data for Amarin’s Vascepa and found little reason to think the mineral oil control arm may have confounded the positive outcome. Now, the agency is asking its ...

Skyhawk’s $80M Celgene deal expands remit to autoimmune

In Skyhawk’s fifth deal of the year, the company is moving into a new therapeutic area and adding $80 million to its cash reserve. Skyhawk partnered with Celgene to discover and develop small ...

Nov. 12 Company Quick Takes: Clinical hold for Solid Bio; plus Foamix-Menlo, Chi-Med, RegeneRx and Actelion

Solid Bio shares sag on news of latest clinical hold FDA has placed a clinical hold on the Phase I/II IGNITE DMD study of gene therapy SGT-001 from Solid Biosciences Inc. (NASDAQ:SLDB) after one of ...

Clinical News

Three late-stage wins shift the clinical landscape in SLE

A trio of companies reported positive data from late-stage systemic lupus erythematosis trials, raising hopes that new treatments are on the horizon for an indication that has seen only one new ...

Bardoxolone data set Reata up to advance second compound toward registration

Weeks after regaining rights to cardiorenal compounds from AbbVie, Reata has reported its second pivotal trial success of the quarter, paving the way for global marketing applications for its two most ...

BioCentury Extra ISSN 2642-3812